Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.... more >

Advanced Accelerator Applications Presentation at 35th Annual J.P. Morgan Healthcare Conference

January 11, 2017
11:30 a.m. PST

Click here for Webcast

Investor Presentation

Latest Newsmore >
01/12/17
Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
SAINT-GENIS-POUILLY, France, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroend... 
01/09/17
Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA
SAINT-GENIS-POUILLY, France, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today issued a statement from Chief Executive Officer, Stefano Buono providing an update on corporate developments of 2016 and outlook for 2017. The statement is included in its entirety below. “The past year has been characterized by rapid growth and advancement across almost every area... 
01/04/17
Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference
SAINT-GENIS-POUILLY, France, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (“MNM”), today announced that the company is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference, January 9-12, 2017, in San Francisco, CA. Stefano Buono, Chief Executive Officer; Gerard Ber, Chief Operating Officer; and Heinz Mäusli, Chief Financial Officer will present o... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources